{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:31:29Z","timestamp":1793766689387,"version":"4.6.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00213-021-05876-x","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T11:03:13Z","timestamp":1626087793000},"page":"1881-1891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Serotonin toxicity of serotonergic psychedelics"],"prefix":"10.1007","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-9036","authenticated-orcid":false,"given":"Benjamin","family":"Malcolm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2818-270X","authenticated-orcid":false,"given":"Kelan","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"5876_CR1","unstructured":"American Psychiatric Association (2010) Practice guideline for the treatment of patients with major depressive disorder.https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"issue":"1","key":"5876_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4037\/ccn2017169","volume":"37","author":"D Bartlett","year":"2017","unstructured":"Bartlett D (2017) Drug-induced serotonin syndrome. Crit Care Nurse 37(1):49\u201354","journal-title":"Crit Care Nurse"},{"issue":"4","key":"5876_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.encep.2015.09.002","volume":"42","author":"A Batisse","year":"2016","unstructured":"Batisse A et al (2016) Cathinones use in Paris. Encephale 42(4):354\u2013360","journal-title":"Encephale"},{"issue":"1\u20132","key":"5876_CR4","first-page":"229","volume":"73","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Murphy DL (1996) Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 73(1\u20132):229\u2013233","journal-title":"Behav Brain Res"},{"issue":"6","key":"5876_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425\u2013436","journal-title":"Neuropsychopharmacology"},{"key":"5876_CR6","doi-asserted-by":"publisher","unstructured":"Boyer EW and Shannon M (2005) The serotonin syndrome.\u00a0New Engl J Med 352(11):1112\u20131120.\u00a0https:\/\/doi.org\/10.1056\/NEJMra041867","DOI":"10.1056\/NEJMra041867"},{"key":"5876_CR7","first-page":"w13115","volume":"140","author":"M Bruggisser","year":"2010","unstructured":"Bruggisser M et al (2010) Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997\u20132009. Swiss Med Wkly 140:w13115","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"5876_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1081\/CLT-120030949","volume":"42","author":"DE Brush","year":"2004","unstructured":"Brush DE, Bird SB, Boyer EW (2004) Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J Toxicol Clin Toxicol 42(2):191\u2013195","journal-title":"J Toxicol Clin Toxicol"},{"issue":"21","key":"5876_CR9","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/0006-2952(77)90007-7","volume":"26","author":"NS Buckholtz","year":"1977","unstructured":"Buckholtz NS, Boggan WO (1977) Monoamine oxidase inhibition in brain and liver produced by beta-carbolines: structure-activity relationships and substrate specificity. Biochem Pharmacol 26(21):1991\u20131996","journal-title":"Biochem Pharmacol"},{"key":"5876_CR10","first-page":"g1626","volume":"348","author":"NA Buckley","year":"2014","unstructured":"Buckley NA, Dawson AH, Isbister GK (2014) Serotonin Syndrome 348:g1626","journal-title":"Serotonin Syndrome"},{"issue":"1","key":"5876_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0196-0644(94)70165-2","volume":"24","author":"CW Callaway","year":"1994","unstructured":"Callaway CW, Clark RF (1994) Hyperthermia in psychostimulant overdose. Ann Emerg Med 24(1):68\u201376","journal-title":"Ann Emerg Med"},{"issue":"4","key":"5876_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/02791072.1998.10399712","volume":"30","author":"JC Callaway","year":"1998","unstructured":"Callaway JC, Grob CS (1998) Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs 30(4):367\u2013369","journal-title":"J Psychoactive Drugs"},{"key":"5876_CR13","doi-asserted-by":"publisher","first-page":"172912","DOI":"10.1016\/j.pbb.2020.172912","volume":"192","author":"Y Chen","year":"2020","unstructured":"Chen Y et al (2020) High ambient temperature increases the toxicity and lethality of 3,4-methylenedioxymethamphetamine and methcathinone. Pharmacol Biochem Behav 192:172912","journal-title":"Pharmacol Biochem Behav"},{"key":"5876_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.forsciint.2015.04.025","volume":"252","author":"J Coelho Neto","year":"2015","unstructured":"Coelho Neto J (2015) Rapid detection of NBOME\u2019s and other NPS on blotter papers by direct ATR-FTIR spectrometry. Forensic Sci Int 252:87\u201392","journal-title":"Forensic Sci Int"},{"issue":"9","key":"5876_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/phar.2163","volume":"38","author":"VL Culbertson","year":"2018","unstructured":"Culbertson VL et al (2018) Implications of off-target serotoninergic drug activity: an analysis of serotonin syndrome reports using a systematic bioinformatics approach. Pharmacotherapy 38(9):888\u2013898","journal-title":"Pharmacotherapy"},{"issue":"10","key":"5876_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","volume":"56","author":"PC Dolder","year":"2017","unstructured":"Dolder PC et al (2017) Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet 56(10):1219\u20131230","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"5876_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/chromsci\/bmw095","volume":"54","author":"B Duffau","year":"2016","unstructured":"Duffau B et al (2016) Analysis of 25 C NBOMe in seized blotters by HPTLC and GC-MS. J Chromatogr Sci 54(7):1153\u20131158","journal-title":"J Chromatogr Sci"},{"key":"5876_CR18","doi-asserted-by":"publisher","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (2003) The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM: J Assoc Physicians 96(9):635\u2013642. https:\/\/doi.org\/10.1093\/qjmed\/hcg109","DOI":"10.1093\/qjmed\/hcg109"},{"issue":"5","key":"5876_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1192\/apt.bp.114.013037","volume":"21","author":"R Ellahi","year":"2018","unstructured":"Ellahi R (2018) Serotonin syndrome: a spectrum of toxicity. Bjpsych Advances 21(5):324\u2013332","journal-title":"Bjpsych Advances"},{"issue":"3","key":"5876_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.107.129056","volume":"323","author":"M Farre","year":"2007","unstructured":"Farre M et al (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323(3):954\u2013962","journal-title":"J Pharmacol Exp Ther"},{"key":"5876_CR21","doi-asserted-by":"publisher","unstructured":"Feduccia AA, Jerome L, Mithoefer MC, Holland J (2021) Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology 238(2):581\u2013588. https:\/\/doi.org\/10.1007\/s00213-020-05710-w","DOI":"10.1007\/s00213-020-05710-w"},{"issue":"11","key":"5876_CR22","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.1971.03190110067020","volume":"217","author":"SA Friedman","year":"1971","unstructured":"Friedman SA, Hirsch SE (1971) Extreme hyperthermia after LSD ingestion. JAMA 217(11):1549\u20131550","journal-title":"JAMA"},{"issue":"1","key":"5876_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1360-0443.2006.01652.x","volume":"102","author":"RS Gable","year":"2007","unstructured":"Gable RS (2007) Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102(1):24\u201334","journal-title":"Addiction"},{"issue":"6","key":"5876_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00002826-200311000-00003","volume":"26","author":"PK Gillman","year":"2003","unstructured":"Gillman PK (2003) Mirtazapine: unable to induce serotonin toxicity? Clin Neuropharmacol 26(6):288\u2013289 (author reply 289-90)","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"5876_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1526-4637.2004.04033.x","volume":"5","author":"PK Gillman","year":"2004","unstructured":"Gillman PK (2004) The spectrum concept of serotonin toxicity. Pain Med 5(2):231\u2013232 (author reply 233)","journal-title":"Pain Med"},{"issue":"4","key":"5876_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/bja\/aei210","volume":"95","author":"PK Gillman","year":"2005","unstructured":"Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95(4):434\u2013441","journal-title":"Br J Anaesth"},{"issue":"2","key":"5876_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1526-4610.2009.01575.x","volume":"50","author":"PK Gillman","year":"2010","unstructured":"Gillman PK (2010a) Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache 50(2):264\u2013272","journal-title":"Headache"},{"issue":"2","key":"5876_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s13181-010-0084-8","volume":"6","author":"PK Gillman","year":"2010","unstructured":"Gillman PK (2010b) Bupropion, bayesian logic and serotonin toxicity. J Med Toxicol 6(2):276\u2013277","journal-title":"J Med Toxicol"},{"issue":"1","key":"5876_CR29","first-page":"105","volume":"1","author":"K Gillman","year":"2017","unstructured":"Gillman K (2017) Monoamine oxidase inhibitors: a review concerning dietary tyramine and drug interactions. PsychoTropical Commentaries 1(1):105","journal-title":"PsychoTropical Commentaries"},{"key":"5876_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1196\/annals.1369.035","volume":"1074","author":"FS Giorgi","year":"2006","unstructured":"Giorgi FS et al (2006) MDMA and seizures: a dangerous liaison? Ann N Y Acad Sci 1074:357\u2013364","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"5876_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3109\/16066350008998989","volume":"8","author":"CS Grob","year":"2000","unstructured":"Grob CS (2000) Deconstructing ecstasy: the politics of MDMA research. Addict Res 8(6):549\u2013588","journal-title":"Addict Res"},{"issue":"5","key":"5876_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S1481803500012598","volume":"12","author":"BE Grunau","year":"2010","unstructured":"Grunau BE, Wiens MO, Brubacher JR (2010) Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM 12(5):435\u2013442","journal-title":"CJEM"},{"issue":"1","key":"5876_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1046\/j.1471-4159.1996.66010243.x","volume":"66","author":"GA Gudelsky","year":"1996","unstructured":"Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66(1):243\u2013249","journal-title":"J Neurochem"},{"key":"5876_CR34","doi-asserted-by":"publisher","unstructured":"Heise CW, Brooks DE (2016) Ayahuasca exposure: descriptive analysis of calls to US poison control centers from 2005 to 2015. J Med Toxicol 13(3):245\u2013248. https:\/\/doi.org\/10.1007\/s13181-016-0593-1","DOI":"10.1007\/s13181-016-0593-1"},{"key":"5876_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pharmthera.2017.10.022","volume":"182","author":"L Hondebrink","year":"2018","unstructured":"Hondebrink L, Zwartsen A, Westerink RHS (2018) Effect fingerprinting of new psychoactive substances (NPS): what can we learn from in vitro data? Pharmacol Ther 182:193\u2013224","journal-title":"Pharmacol Ther"},{"issue":"5","key":"5876_CR36","doi-asserted-by":"publisher","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM et al (2012) Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE 7(5):e36476","journal-title":"PLoS ONE"},{"key":"5876_CR37","unstructured":"International Center for Ethnobotanical Education and Research (ICEER) (2017)\u00a0 Risks associated with combining Bufo Alvarius with ayahuasca.\nhttps:\/\/www.iceers.org\/risks-associated-with-combining-bufo-alvarius-with-ayahuasca\/"},{"issue":"5","key":"5876_CR38","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1124\/dmd.112.050724","volume":"41","author":"XL Jiang","year":"2013","unstructured":"Jiang XL et al (2013) Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N, N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metab Dispos 41(5):975\u2013986","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"5876_CR39","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/j.1476-5381.2011.01499.x","volume":"164","author":"J Kehr","year":"2011","unstructured":"Kehr J et al (2011) Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164(8):1949\u20131958","journal-title":"Br J Pharmacol"},{"issue":"2","key":"5876_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/15563657508988063","volume":"8","author":"JC Klock","year":"1975","unstructured":"Klock JC, Boerner U, Becker CE (1975) Coma, hyperthermia, and bleeding associated with massive LSD overdose a report of eight cases. Clin Toxicol 8(2):191\u2013203","journal-title":"Clin Toxicol"},{"key":"5876_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.12688\/f1000research.2-98.v1","volume":"2","author":"TS Krebs","year":"2013","unstructured":"Krebs TS, Johansen P-\u00d8 (2013) Over 30 million psychedelic users in the United States. F1000Res 2:98\u201398","journal-title":"F1000Res"},{"issue":"1","key":"5876_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.102.042184","volume":"304","author":"DM Kurrasch-Orbaugh","year":"2003","unstructured":"Kurrasch-Orbaugh DM et al (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304(1):229\u2013237","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"5876_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/026988110001400313","volume":"14","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (\u2018ecstasy\u2019) in healthy volunteers. J Psychopharmacol 14(3):269\u2013274","journal-title":"J Psychopharmacol"},{"issue":"12","key":"5876_CR44","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0269881118793086","volume":"32","author":"JB Leonard","year":"2018","unstructured":"Leonard JB, Anderson B, Klein-Schwartz W (2018) Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol 32(12):1286\u20131294","journal-title":"J Psychopharmacol"},{"issue":"11","key":"5876_CR45","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/npp.2017.86","volume":"42","author":"ME Liechti","year":"2017","unstructured":"Liechti ME (2017) Modern clinical research on LSD. Neuropsychopharmacology 42(11):2114\u20132127","journal-title":"Neuropsychopharmacology"},{"key":"5876_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.neuropharm.2017.07.026","volume":"134","author":"D Luethi","year":"2018","unstructured":"Luethi D et al (2018) Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology 134:4\u201312","journal-title":"Neuropharmacology"},{"issue":"1","key":"5876_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.9740\/mhc.2017.01.039","volume":"7","author":"BJ Malcolm","year":"2017","unstructured":"Malcolm BJ, Lee KC (2017) Ayahuasca: an ancient sacrament for treatment of contemporary psychiatric illness? Ment Health Clin 7(1):39\u201345","journal-title":"Ment Health Clin"},{"key":"5876_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0021-8707(63)90089-3","volume":"34","author":"E Mathov","year":"1963","unstructured":"Mathov E (1963) The risks of monoamine oxidase inhibitors in the treatment of bronchial asthma. J Allergy 34:483\u2013488","journal-title":"J Allergy"},{"issue":"11","key":"5876_CR49","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/0006-3223(91)90182-L","volume":"30","author":"DJ McManus","year":"1991","unstructured":"McManus DJ et al (1991) Beta-adrenoceptors and antidepressants: possible 2-phenylethylamine mediation of chronic phenelzine effects. Biol Psychiatry 30(11):1122\u20131130","journal-title":"Biol Psychiatry"},{"issue":"4","key":"5876_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC et al (2011) The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25(4):439\u2013452","journal-title":"J Psychopharmacol"},{"issue":"9","key":"5876_CR51","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer MC et al (2019) MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236(9):2735\u20132745","journal-title":"Psychopharmacology"},{"issue":"2","key":"5876_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131\u2013181","journal-title":"Pharmacol Ther"},{"issue":"2","key":"5876_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355","journal-title":"Pharmacol Rev"},{"key":"5876_CR54","first-page":"1","volume":"36","author":"DE Nichols","year":"2018","unstructured":"Nichols DE (2018) Chemistry and structure-activity relationships of psychedelics. Curr Top Behav Neurosci 36:1\u201343","journal-title":"Curr Top Behav Neurosci"},{"key":"5876_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","volume":"284","author":"DE Nichols","year":"2018","unstructured":"Nichols DE, Grob CS (2018) Is LSD toxic? Forensic Sci Int 284:141\u2013145","journal-title":"Forensic Sci Int"},{"issue":"12","key":"5876_CR56","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1248\/bpb.30.2328","volume":"30","author":"R Nonaka","year":"2007","unstructured":"Nonaka R et al (2007) In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes. Biol Pharm Bull 30(12):2328\u20132333","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"5876_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/02791072.1999.10471741","volume":"31","author":"J Ott","year":"1999","unstructured":"Ott J (1999) Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoactive Drugs 31(2):171\u2013177","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"5876_CR58","first-page":"585","volume":"40","author":"JH Pardanani","year":"1977","unstructured":"Pardanani JH et al (1977) Cactus alkaloids. XXXVI. Mescaline and related compounds from Trichocereus peruvianus. Lloydia 40(6):585\u2013590","journal-title":"Lloydia"},{"issue":"1","key":"5876_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/070674370104600112","volume":"46","author":"V Parker","year":"2001","unstructured":"Parker V et al (2001) Adverse reactions to St John\u2019s wort. Can J Psychiatry 46(1):77\u201379","journal-title":"Can J Psychiatry"},{"issue":"1\u20132","key":"5876_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2011.08.012","volume":"121","author":"AC Parrott","year":"2012","unstructured":"Parrott AC (2012a) MDMA and temperature: a review of the thermal effects of \u2018ecstasy\u2019 in humans. Drug Alcohol Depend 121(1\u20132):1\u20139","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"5876_CR61","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/j.1476-5381.2012.01941.x","volume":"166","author":"AC Parrott","year":"2012","unstructured":"Parrott AC (2012b) MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation. Br J Pharmacol 166(5):1518\u20131520 (discussion 1521-2)","journal-title":"Br J Pharmacol"},{"issue":"1\u20133","key":"5876_CR62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.forsciint.2011.04.008","volume":"215","author":"JL Pilgrim","year":"2012","unstructured":"Pilgrim JL et al (2012) Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int 215(1\u20133):184\u2013188","journal-title":"Forensic Sci Int"},{"key":"5876_CR63","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","volume":"99","author":"A Rickli","year":"2015","unstructured":"Rickli A et al (2015) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546\u2013553","journal-title":"Neuropharmacology"},{"issue":"8","key":"5876_CR64","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A et al (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26(8):1327\u20131337","journal-title":"Eur Neuropsychopharmacol"},{"key":"5876_CR65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainres.2012.10.057","volume":"1491","author":"EA Schindler","year":"2013","unstructured":"Schindler EA, Harvey JA, Aloyo VJ (2013) Phospholipase C mediates (\u00b1)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex. Brain Res 1491:98\u2013108","journal-title":"Brain Res"},{"key":"5876_CR66","doi-asserted-by":"publisher","first-page":"117864691987392","DOI":"10.1177\/1178646919873925","volume":"12","author":"WJ Scotton","year":"2019","unstructured":"Scotton WJ et al (2019) Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res 12:1178646919873925","journal-title":"Int J Tryptophan Res"},{"issue":"8","key":"5876_CR67","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/138920010794233495","volume":"11","author":"HW Shen","year":"2010","unstructured":"Shen HW et al (2010) Psychedelic 5-methoxy-N, N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 11(8):659\u2013666","journal-title":"Curr Drug Metab"},{"issue":"1","key":"5876_CR68","first-page":"46","volume":"36","author":"AT Shulgin","year":"1973","unstructured":"Shulgin AT (1973) Mescaline: the chemistry and pharmacology of its analogs. Lloydia 36(1):46\u201358","journal-title":"Lloydia"},{"key":"5876_CR69","volume-title":"Pihkal: a chemical love story","author":"AT Shulgin","year":"1991","unstructured":"Shulgin AT, Shulgin A (1991) Pihkal: a chemical love story. Transform Press, Berkeley"},{"key":"5876_CR70","volume-title":"Tihkal : the continuation","author":"A Shulgin","year":"2016","unstructured":"Shulgin A, Shulgin A, Transform P (2016) Tihkal\u202f: the continuation. Transform Press, Berkeley"},{"key":"5876_CR71","unstructured":"Simon LV (2019) Serotonin syndrome. [Updated 2019 Nov 24], In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482377\/"},{"issue":"8","key":"5876_CR72","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/jat\/29.8.838","volume":"29","author":"J Sklerov","year":"2005","unstructured":"Sklerov J et al (2005) A fatal intoxication following the ingestion of 5-methoxy-N, N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol 29(8):838\u2013841","journal-title":"J Anal Toxicol"},{"issue":"7","key":"5876_CR73","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4088\/JCP.v60n0711a","volume":"60","author":"DJ Stein","year":"1999","unstructured":"Stein DJ, Rink J (1999) Effects of \u201cecstasy\u201d blocked by serotonin reuptake inhibitors. J Clin Psychiatry 60(7):485","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"5876_CR74","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1176\/ajp.148.6.705","volume":"148","author":"H Sternbach","year":"1991","unstructured":"Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148(6):705\u2013713","journal-title":"Am J Psychiatry"},{"issue":"2","key":"5876_CR75","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.psym.2014.11.002","volume":"56","author":"J Suzuki","year":"2015","unstructured":"Suzuki J et al (2015) Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics 56(2):129\u2013139","journal-title":"Psychosomatics"},{"issue":"4","key":"5876_CR76","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","volume":"189","author":"M Tancer","year":"2007","unstructured":"Tancer M, Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189(4):565\u2013573","journal-title":"Psychopharmacology"},{"key":"5876_CR77","unstructured":"Thomas K (2019) Why Chronic Microdosing Might Break Your Heart. Chacruna.net. https:\/\/chacruna.net\/why-chronic-microdosing-might-break-yourheart\/"},{"key":"5876_CR78","doi-asserted-by":"publisher","unstructured":"Thomas K, Malcolm B, Lastra D (2017) Psilocybin-assisted therapy: a review of a novel treatment for psychiatric disorders. J Psychoactive Drugs: 49(5):446\u2013455. https:\/\/doi.org\/10.1080\/02791072.2017.1320734","DOI":"10.1080\/02791072.2017.1320734"},{"key":"5876_CR79","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/B978-0-444-64074-1.00039-2","volume":"157","author":"LM Tormoehlen","year":"2018","unstructured":"Tormoehlen LM, Rusyniak DE (2018) Neuroleptic malignant syndrome and serotonin syndrome. Handb Clin Neurol 157:663\u2013675","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"5876_CR80","first-page":"05","volume":"11","author":"MF Uddin","year":"2017","unstructured":"Uddin MF et al (2017) Controversies in serotonin syndrome diagnosis and management: a review. J Clin Diagn Res 11(9):05\u201307","journal-title":"J Clin Diagn Res"},{"key":"5876_CR81","unstructured":"Veterans Affairs Department of Defense (2017) Management of Posttraumatic Stress Disorder and Acute Stress Reaction. https:\/\/www.healthquality.va.gov\/guidelines\/MH\/ptsd\/"},{"issue":"9","key":"5876_CR82","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11(9):642\u2013651","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"5876_CR83","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1360-0443.2003.00292.x","volume":"98","author":"E Vuori","year":"2003","unstructured":"Vuori E et al (2003) Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98(3):365\u2013368","journal-title":"Addiction"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05876-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T07:05:29Z","timestamp":1654239929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05876-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5876"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05876-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}